Scopus BioPharma (Scopus BioPharma) Other Long Term Assets : $0.00 Mil (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Scopus BioPharma Other Long Term Assets?

Scopus BioPharma's other long-term assets for the quarter that ended in Jun. 2023 was $0.00 Mil.

Scopus BioPharma's quarterly other long-term assets stayed the same from Dec. 2022 ($0.00 Mil) to Mar. 2023 ($0.00 Mil) and stayed the same from Mar. 2023 ($0.00 Mil) to Jun. 2023 ($0.00 Mil).

Scopus BioPharma's annual other long-term assets increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($0.00 Mil) but then declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil).

Scopus BioPharma Other Long Term Assets Historical Data

The historical data trend for Scopus BioPharma's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scopus BioPharma Other Long Term Assets Chart

Scopus BioPharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Other Long Term Assets

Get a 7-Day Free Trial

Scopus BioPharma Quarterly Data
	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Other Long Term Assets	Get a 7-Day Free Trial															-	-	-	-	-

Scopus BioPharma Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Scopus BioPharma (Scopus BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scopus BioPharma Inc (OTCPK:SCPS) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 300, New York, NY, USA, 10170

Website

https://www.scopusbiopharma.com

Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. The company product candidates would utilize synthetically-produced cannabinoids as opposed to plant-derived compounds. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.

Executives

Ira Scott Greenspan	director	888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106
Joshua R Lamstein	director, officer: Chairman	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Alan M Horsager	officer: See Remarks	1021 N EVERETT STREET, GLENDALE CA 91207
Robert J Gibson	director, officer: Vice Chairman	71 LANTERN RIDGE RD, NEW CANAAN CT 06840
Lesley Russell	director	41 MOORES RD., FRAZER PA 19355
Iv David Weild	director	22 ORIOLE AVENUE, BRONXVILLE NY 10708
David S. Battleman	director	C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
David A. Buckel	director	SHARPSPRING, 550 SW 2ND AVENUE, GAINESVILLE FL 32601
Raphael Hofstein	director	C/O HADASSAH, P.O. BOX 12000, JERUSALEM L3 91120
Paul Hopper	director	7982 DOUG HILL, SAN DIEGO CA 92127
Ashish P Sanghrajka	director, officer: President	101 WALL STREET, APARTMENT 19B, NEW YORK NY 10005